Detalhe da pesquisa
1.
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
Immunity
; 54(8): 1825-1840.e7, 2021 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34270940
2.
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Gut
; 71(7): 1277-1288, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433583
3.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 23(1): 77-90, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914889
4.
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Int J Cancer
; 151(3): 435-449, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35415893
5.
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
J Hepatol
; 77(3): 683-694, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35430299
6.
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
J Hepatol
; 75(3): 600-609, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051329
7.
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
J Hepatol
; 72(2): 307-319, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31954494
8.
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
J Hepatol
; 71(3): 543-552, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31176752
9.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Lancet
; 389(10088): 2492-2502, 2017 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28434648
10.
Atezolizumab and bevacizumab for HCC in the real world.
Liver Int
; 42(4): 727-728, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35289074
11.
201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre.
Int J Hyperthermia
; 33(3): 288-294, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27855557
12.
Comparison of health state values derived from patients and individuals from the general population.
Qual Life Res
; 26(12): 3353-3363, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28808840
13.
Comparison of hepatocellular carcinoma in Eastern versus Western populations.
Cancer
; 122(22): 3430-3446, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27622302
14.
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
BMC Cancer
; 16(1): 856, 2016 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27821083
15.
A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.
HPB (Oxford)
; 18(1): 7-12, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26776845
16.
A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.
HPB (Oxford)
; 2015 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26472490
17.
Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].
J Hepatol
; 71(6): 1278, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31668671
18.
Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Asia Pac J Clin Oncol
; 19(3): 312-319, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950298
19.
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
J Clin Oncol
; 41(9): 1747-1757, 2023 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512738
20.
Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.
Front Immunol
; 14: 1150985, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37342338